[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arthritis-rheumatoid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arthritis-rheumatoid":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,43,71,96,116,139,160,192,219,245,269,297,328,353,384,406,425,452,476,498,521],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100513140","phase-1-r-2487-in-patients-with-rheumatoid-arthritis-100513140",false,"NCT05961592","R-2487 in Patients With Rheumatoid Arthritis","A Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients With Rheumatoid Arthritis","R-2487-RA01","Inclusion Criteria:\n\n* Ages 18-75 years (Inclusive).\n* Able to provide written informed consent.\n* Men or women (not nursing or pregnant) who have active RA, defined as symptoms of RA prior to screening and have satisfied the ACR\u002FEULAR 2010 criteria for the classification of RA prior to signing the informed consent.\n* Subjects must have a CDAI \\> 10.0 at screening and have at least 3 tender and at least 3 swollen joints (excluding distal interphalangeal) at screening and at Day 1, based on the DAS28 joint count.\n* Subjects may be able to be on hydroxychloroquine, methotrexate, and leflunomide. Sulfasalazine use is not permitted.\n* Subjects may have received targeted synthetic DMARDs such as tofacitinib, baricitinib, and investigational therapies for RA if they have been washed out for 1 month prior to screening.\n* Subjects receiving oral corticosteroids must be on a stable dose and at the equivalent of ≤10 mg prednisone daily for at least 4 weeks. Subjects may not receive an IM, IV or IA administration of a corticosteroid within 4 weeks prior to screening visit or initiation of therapy.\n* All male and female subjects who are biologically capable of having children must agree to use a medically acceptable method of birth control for the duration of the study. All female subjects who are biologically capable of having children must have a negative pregnancy test result before administration of study drug. Any pregnancy that occurs in the female partner of a male subject in the trial must be reported if it occurs at any time during the study.\n* Refrain from receiving any type of vaccinations during the study period (to include but not limited to influenza, COVID, shingles, tetanus, hepatitis, pneumonia, HPV, DPT, MMR, and polio).\n\nExclusion Criteria:\n\n* Pregnancy (females, unless surgically sterile or at least two years post- menopausal must have a negative serum pregnancy test within 14 days prior to receiving the study drug and a negative urine pregnancy test on Study Day 0 before receiving the study drug).\n* Nursing mothers.\n* Subjects with autoimmune disease other than RA \\[e.g., psoriasis, systemic lupus erythematosus (SLE), vasculitis, seronegative spondylarthritis, Inflammatory Bowel Disease, Sjogren's syndrome\\] or currently active fibromyalgia.\n* Subjects should not receive any of the following medications:\n* Rituximab within 12 months prior to Day 1,\n* Abatacept within 3 months prior to Day 1,\n* Infliximab, Adalimumab, Certolizumab, Tocilizumab, Cyclosporine, or\n* Mycophenolate mofetil within 2 months prior to Day 1, or\n* Etanercept, Anakinra, Immunoglobulin, or blood products within 28 days prior to Day 1\n* Prior immunotherapy, including systemic corticosteroids, such prednisone, biologics, Janus kinase (JAK) inhibitors (such as tofacitinib, baricitinib or upadacitinib), ozanimod, or investigational therapy must have completed at least 5 half-lives or 30 days, whichever is longer, prior to Day 0, unless otherwise specified. In the case of cell-depleting therapies, such as B or T cell depletion, cell counts must have recovered to acceptable or baseline levels (use of licensed agents for indications not listed in the package insert is permitted).\n* Prior history of or current inflammatory joint disease other than RA (such as psoriatic arthritis, gout, reactive arthritis, Lyme disease).\n* Subjects at risk for tuberculosis (TB) defined as follows: Current clinical, radiographic or laboratory evidence of active TB. Chest x-rays (posterior, anterior and lateral) obtained within the 3 months prior to obtaining written informed consent will be permitted but the images must be available and reviewed by the investigator. TB testing (IFN-gamma release assay or PPD) performed in the past month prior to Screening will be accepted; however, a copy of the report must be placed in the subject binder.\n* A history of active TB.\n* Subjects with a positive TB screening test indicative of latent TB including subjects currently being treated for latent tuberculosis infection (LTBI) will not be eligible for the study.\n* Subjects with recent acute infection defined as:\n* Any acute infection within 60 days prior to randomization that required hospitalization or treatment with parenteral antibiotics,\n* Any acute infection within 30 days prior to randomization that required oral antimicrobial or antiviral therapy,\n* Subjects with history of chronic or recurrent bacterial infection (such as chronic pyelonephritis, osteomyelitis, and bronchiectasis etc.),\n* Subjects with any history of infection of a joint prosthesis or artificial joint,\n* Subjects who have a history of systemic fungal infections (such as histoplasmosis, blastomycosis, or coccidiomycosis),\n* Subjects with history of recurrent herpes zoster (more than 1 episode) or disseminated (more than 1 dermatome) herpes zoster or disseminated herpes simplex, or ophthalmic zoster will be excluded,\n* Symptoms of herpes zoster or herpes simplex must have resolved more than 60 days prior to screening,\n* Subjects with history of primary immunodeficiency.\n* Subjects with history of Human Immunodeficiency Virus (HIV) infection or who tested positive for HIV.\n* Evidence of infection with hepatitis B virus (HBV), hepatitis C virus (C), human immunodeficiency virus (HIV)-1 or HIV-2, or active infection with hepatitis A, as determined by results of testing at screening.\n* Subjects who have a present malignancy or previous malignancy within the last 5 years prior to screening (except documented history of cured non- metastatic squamous or basal cell skin carcinoma or cervical carcinoma in situ). Subjects who had a screening procedure that is suspicious for malignancy, and in whom the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory or other diagnostic evaluations.\n* Current clinical findings of a history of a demyelinating disorder.\n* New York Heart Association (NYHA) Class III or IV heart failure.\n* Subjects who have undergone a major surgical procedure within the 60 days prior to enrollment.\n* Subjects for whom 5 or more joints cannot be assessed for tenderness or swelling (i.e. due to surgery, fusion, amputation, etc.).\n* Current clinical findings of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, endocrine, neurological, or cerebral disease with laboratory values as following:\n* Hemoglobin level \\\u003C 9.0 g\u002FdL,\n* Absolute white blood cell (WBC) count of \\\u003C3.0×109\u002FL (\\\u003C3000\u002Fmm3), or absolute neutrophil count of \\\u003C1.2×109\u002FL (\\\u003C1200\u002Fmm3), or absolute lymphocyte count of \\\u003C0.8×109\u002FL (\\\u003C800\u002Fmm3),\n* Thrombocytopenia, defined by platelet count \\\u003C100×109\u002FL (\\\u003C100,000\u002Fmm3),\n* Chronic kidney disease defined as Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73m2, based on the age-appropriate calculation,\n* Proteinuria ≥3+,\n* Total bilirubin (T-bili), aspartate aminotransferase (AST), alanine aminotransferase (ALT) more than 1.5 times upper limit of normal (ULN)\n* Previously diagnosed hepatic cirrhosis (Child Pugh A or higher) or previously diagnosed significant liver fibrosis (\\> F3).\n* Any form of vaccination in the last 30 days, to include but not limited to influenza, COVID, shingles, tetanus, hepatitis, pneumonia, HPV, DPT, MMR, and polio.","ALL","18 Years","75 Years",{"count":21,"type":22},73,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Rheumatoid Arthritis.\n\nPatients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Rheumatoid Arthritis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.",[28],"Arthritis, Rheumatoid",[28],"RECRUITING","2026-06-10",{"date":33,"type":34},"2026-06-12","ACTUAL",{"date":36,"type":34},"2023-10-19",{"date":38,"type":22},"2026-12-31",{"name":40,"class":41},"Rise Therapeutics LLC","INDUSTRY",6,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100534999","a-study-of-jyseleca-tablet-filgotinib-maleate-in-korean-participants-100534999","NCT06246123","A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants","Post Marketing Surveillance of Jyseleca Tab. (Filgotinib Maleate) in Korean Subjects","Inclusion Criteria:\n\n1\\. Individuals who are being administered with Jyseleca tablet in accordance with the Korean approved label therapeutic indications.\n\n* Korean local label therapeutic indications of Jyseleca tablet. In the following participants, Jyseleca tablet should be used only if they do not respond appropriately or are intolerant to existing treatments.\n* Following:\n\n  1. Participants over 65 years of age.\n  2. Participants with a high cardiovascular risk.\n  3. Participants with malignancy.\n* Rheumatoid arthritis:\n\n  1. For treatment of moderately to severely active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).\n  2. Jyseleca tablet may be used as monotherapy or in combination with methotrexate (MTX).\n  3. Jyseleca tablet should not be used in combination with biological DMARDs (bDMARDs) or other Janus kinase (JAK) inhibitors.\n* Ulcerative colitis:\n\n  a. For treatment of moderately to severely active ulcerative colitis in adults who have an inadequate response with, lost response to, or were intolerant to either conventional therapy (corticosteroids, immunosuppressants, etc.) or biological agents.\n* The investigator should refer to local label and contraindications in Korea regarding the inclusion criteria.\n\nExclusion Criteria:\n\n1. Individuals who fall under contraindications to the administration of Jyseleca tablet in accordance with the local label by the medical judgment of the investigator.\n\n   * Contraindication for Jyseleca tablet in accordance with the Korean label:\n\n     1. Participants with hypersensitivity to the active ingredient or other ingredients of the Jyseleca tablet.\n     2. Participants with active infections, including serious (example, sepsis) or local infections.\n     3. Participants with active tuberculosis.\n     4. Participants with severe hepatic disorder.\n     5. Participants with end-stage renal disorder.\n     6. Participants with absolute neutrophil count (ANC) \\\u003C1\\*10\\^9 cells\u002Fliters (L)\n     7. Participants with absolute lymphocyte count (ALC) \\\u003C0.5\\*10\\^9 cells\u002FL\n     8. Participants with hemoglobin level \\\u003C8 grams per deciliter (g\u002FdL)\n     9. Pregnant or potentially pregnant women, lactating women\n     10. Jyseleca tablet should not be administered to participants with genetic problems such as galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption as it contains lactose.\n2. Individuals who are administered Filgotinib in a clinical study other than this post marketing surveillance.\n3. Individuals who are considered incompatible with participate in this surveillance by the medical judgment of the investigator.\n\n   * The investigator should refer to local label and contraindications in Korea regarding the exclusion criteria.",{"count":51,"type":22},2040,"OBSERVATIONAL","The purpose of this study is to collect and evaluate the following information in relation to the safety and the efficacy of Jyseleca tablet (Filgotinib Maleate) 100 milligram (mg) and 200 mg in this post marketing setting: (1) Serious adverse events and adverse drug reactions (2) Unexpected adverse events and adverse drug reactions not reflected in precautions for use (3) Known adverse drug reactions (4) Non-serious adverse events and adverse drug reactions (5) Other safety and effectiveness related information will be evaluated in accordance with the permitted articles under the actual conditions of use in Korea.",[28,55],"Colitis, Ulcerative",[57,58,59,60],"Filgotinib Maleate","Rheumatoid arthritis","Ulcerative colitis","FIL-M082-501","2026-05-21",{"date":63,"type":34},"2026-05-22",{"date":65,"type":34},"2024-02-27",{"date":67,"type":22},"2027-07-30",{"name":69,"class":41},"Eisai Korea Inc.",65,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":95},"100596471","fucoidan-in-the-treatment-of-active-rheumatoid-arthritis-100596471","NCT07045896","Fucoidan in the Treatment of Active Rheumatoid Arthritis","Fucoidan Therapy in Adults With Active Rheumatoid Arthritis and Inadequate Response to Conventional DMARDs: a Multicenter, Single-arm, Open-label, Phase 2 Trial","Inclusion Criteria:\n\n* Patients aged 18-65 years (inclusive) at screening, regardless of gender, with a minimum weight of 35 kg.\n* Patients meeting the 2010 ACR classification criteria for rheumatoid arthritis.\n* Patients with active rheumatoid arthritis showing moderate-to-high disease activity (DAS28-ESR \\>3.2) despite current treatment.\n* If receiving conventional NSAIDs or other pain medications, the dose must have been stable for at least 2 weeks prior to the first study drug administration and remain unchanged during the study period.\n* If taking oral corticosteroids, patients must have been on treatment for at least 4 weeks, with the dose stabilized at an average of ≤1.0 mg\u002Fkg\u002Fday prednisone equivalent for at least 4 weeks prior to the first study drug administration, and remain unchanged during the study period.\n* If receiving DMARDs (methotrexate ≤25 mg\u002Fweek with folic acid supplementation \\[recommended ≥5 mg\u002Fweek\\] or leflunomide ≤40 mg\u002Fday), patients must have been on treatment for ≥8 weeks, with the dose stable for at least 4 weeks prior to the first study drug administration, and remain unchanged during the study period.\n* Female patients of childbearing potential must have negative serum and urine pregnancy test results at screening.\n* From the time of signing the informed consent form throughout the study and for 3 months after the last dose, female patients of childbearing potential and male patients who have not undergone vasectomy must use effective contraception.\n* Patients must be willing and able to comply with the study restrictions.\n* Patients must sign the informed consent form, understand the purpose and procedures of the study, and be willing to participate in the study.\n\nExclusion Criteria:\n\n* Patients currently receiving biologic therapy.\n* Patients with other inflammatory joint diseases or connective tissue diseases.\n* Patients with significant bone marrow impairment or significant anemia, leukopenia, or thrombocytopenia secondary to inactive rheumatoid arthritis.\n* Patients with persistent or severe infections within 3 months prior to enrollment.\n* Patients with uncontrolled hypertension, uncontrolled diabetes, unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcers, terminal illnesses, or other conditions that, in the investigator's opinion, would pose a risk to the patient's participation in the study.\n* Patients with clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic diseases that would complicate the implementation of the protocol or interpretation of study results.\n* Patients with severe hypoalbuminemia (serum albumin \\\u003C30 g\u002FL), such as due to severe liver disease or nephrotic syndrome.\n* Patients with moderate or severe renal impairment, defined as serum creatinine \\>133 μmol\u002FL (or 1.5 mg\u002FdL).\n* Patients with a recent or clinically significant history of drug or alcohol abuse.\n* Patients with impaired liver function or persistent alanine aminotransferase levels \\>2 times the upper limit of normal.\n* Pregnant patients.\n* Breastfeeding patients.\n* Patients with congenital or acquired severe immunodeficiency, a history of cancer or lymphoproliferative disorders, or those who have undergone total lymphoid irradiation.\n* Patients with known HIV-positive status.\n* Patients with known positive serology for hepatitis B or hepatitis C.\n* Patients enrolled in any other clinical trial involving off-label use of investigational drugs or devices, or enrolled in any other type of medical research.\n* Patients with any active infection (including chronic or localized infections) requiring antimicrobial therapy within 28 days prior to the first study drug dose.\n* Patients with a body mass index (BMI) \\\u003C18.5 kg\u002Fm² or \\>30 kg\u002Fm².","65 Years",{"count":80,"type":22},40,[82],"NA","Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint destruction and autoantibody production. Scavenger receptor-A (SR-A), a pattern recognition receptor primarily expressed on myeloid-derived cells, is significantly elevated in the serum of RA patients. Genetic knockout of SR-A completely protects mice from collagen-induced arthritis (CIA). As an SR-A inhibitor, fucoidan markedly suppresses the progression of CIA in mice. Given the potential role of SR-A in RA pathogenesis, the investigators hypothesize that fucoidan may exert therapeutic effects in RA by specifically targeting human SR-A.\n\nThis study aims to investigate the efficacy of fucoidan in RA treatment through a multicenter, single-arm, open-label trial, providing original insights into its clinical application. The investigators plan to enroll 40 patients with a 12-week follow-up period. Clinical manifestations, laboratory parameters, and disease activity will be systematically evaluated to assess therapeutic outcomes. The findings will provide evidence-based medical data for RA treatment strategies.",[28],"2026-04-14",{"date":87,"type":34},"2026-04-17",{"date":89,"type":34},"2026-01-10",{"date":91,"type":22},"2027-07",{"name":93,"class":94},"Peking University People's Hospital","OTHER",1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":95},"100517359","application-of-the-personalized-n-of-1-trial-design-in-patients-with-rheumatoid-arthritis-100517359","NCT06016517","Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis","In order to be eligible to participate in this study, a subject must meet all the following criteria:\n\n* Newly diagnosed adult-onset Rheumatoid Arthritis (RA) as defined by the American College of Rheumatology\u002F European League Against Rheumatism (ACR\u002FEULAR) 2021 Criteria for the Classification of RA\n* Moderately to severely active RA defined as the presence of at least 6\u002F68 tender joints and at least 6\u002F66 swollen joints\n* C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP) measurement ≥ 1 time the upper limit of normal\n* First-line therapy with MTX for at least the 12 weeks prior to study entry with a continuous, non-changing dose for at least 8 weeks prior to study entry but continue to exhibit active RA\n* Had to discontinue MTX due to intolerability or toxicity, irrespective of treatment duration\n* Have never received etanercept, adalimumab, upadacitinib, or tocilizumab prior to first dose of study drug.\n* Provision of informed consent in English or another language in which a validated consent form is available, or via short-form consent with the assistance of a qualified interpreter.\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* 18 years of age or older\n* Ability to take oral medication and be willing to adhere to all treatment periods\n* Patients are eligible whether their disease responded partially or inadequately to first-line MTX or if they were intolerant to first-line MTX\n* Enrollment in an insurance plan that participates in or is subscribed to this trial\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA\n* Has received intra-articular, intravenous, intramuscular corticosteroids within 28 days prior to baseline\n* Known allergic reactions to components of any of the investigative biologic agents\n* Is currently receiving corticosteroids at doses \\> (greater than) 10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization\n* Has experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or have New York Heart Association stage IV heart failure\n* Tuberculosis infection\n* Hepatitis B or C infection\n* History of venous thromboembolic event (deep vein thrombosis, pulmonary embolism)\n* Has a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and\u002For unstable illness that, in the opinion of the investigator, could constitute a risk or could interfere with the interpretation of data\n* Has an estimated glomerular filtration rate (eGFR) based on the most recent available serum creatinine of \\\u003C (less than) 40 milliliter per minute per 1.73 m\\^2 (mL\u002Fmin\u002F1.73 m\\^2)\n* Has a history of chronic liver disease with the most recent available aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>1.5 times the ULN or the most recent available total bilirubin ≥1.5 times the ULN\n* Has a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for \\\u003C5 years\n* Has been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to need\u002Freceive a live vaccine during the course of the study (with the exception of herpes zoster vaccination)\n* Has a current or recent clinically serious viral, bacterial, fungal, or parasitic infection\n* Has had symptomatic herpes zoster infection within 12 weeks prior to study entry\n* Has immunocompromising condition and, in the opinion of the investigator, are at an unacceptable risk for participating in the study and using these medications\n* Has a history of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)\\*\n* Has evidence of active or latent tuberculosis (TB)\n* Current hospitalization or requiring hospital admission at screening\n* Pregnant or breastfeeding\n* Of childbearing potential, unwilling to use effective birth control method (highly effective contraceptive measure (e.g., combined (estrogen and progestogen containing) hormonal contraception; intrauterine device)\n* Participation in another therapeutic clinical trial for RA\n* Lack of internet access to telehealth platform\n\nState who will determine eligibility. Note that those who are designated to determine eligibility must have appropriate training, expertise, and oversight, for example a physician PI or Co-I on a biomedical study: Eligibility will be determined by the appropriately trained and delegated physician investigator or physician Co- investigator.",{"count":103,"type":22},18,"The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available. The treatments are different in how they work, the way they are given, side- effects, and cost. While treatment guidelines are available, finding the best treatment order of treatments is often based on physician choice. The main question this study aims to answer are:\n\n* What are the effects of different treatments on RA symptoms and condition for each individual patient\n* What is the effectiveness of different treatments across all patients enrolled in the N-of-1 study\n\nParticipants will be enrolled and randomized to a sequence of three U.S. Food and Drug Administration (FDA) approved RA medications: 1. etanercept, 2. adalimumab, 3. upadacitinib 4. tocilizumab. Participants will be asked to complete questionnaires about their condition and quality of life fortnightly, monthly and\u002For quarterly (either in clinic or remotely) and report their level of pain on alternate days (remotely).",[28],"NOT_YET_RECRUITING","2026-04-08",{"date":109,"type":34},"2026-04-13",{"date":111,"type":22},"2026-05-01",{"date":113,"type":22},"2028-12-01",{"name":115,"class":94},"Tufts Medical Center",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100624674","phase-1-a-study-of-bms-986528-in-participants-with-refractory-rheumatoid-arthritis-100624674","NCT07412704","A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis","A Phase 1\u002F2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants With Refractory Rheumatoid Arthritis","Inclusion Criteria\n\n\\- Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat.\n\nExclusion Criteria\n\n* Juvenile arthritis or onset of inflammatory arthritis before age 18.\n* Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out.\n* Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":124,"type":22},84,[25,126],"PHASE2","The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).",[28],"2026-02-20",{"date":131,"type":34},"2026-02-23",{"date":133,"type":22},"2026-05-28",{"date":135,"type":22},"2030-09-02",{"name":137,"class":41},"Bristol-Myers Squibb",31,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":145,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":95},"100113926","laser-based-photoacoustic-tomography-of-human-inflammatory-arthritis-100113926","NCT00748254","Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis","Inclusion Criteria:\n\n* Men and women 18 years of age or older can participate in this study.\n* Patients can participate in this study if they have had rheumatoid arthritis for more than 2 years and their rheumatologist has referred them to this study.\n* Patients can participate as a healthy volunteer with a known history of rheumatoid arthritis.\n\nExclusion Criteria:\n\n* Patients, who have electrically, magnetically or mechanically activated implants such as heart pacemaker, magnetic surgical clips, prostheses or implanted neurological stimulator.\n* Pregnant patients.\n* Patients who is claustrophobic.\n* Patients with impaired renal function cannot participate in this study such as elevate creatinine clearance, patients on kidney dialysis etc.\n* Patients with shock hypotension or unstable low blood pressure.\n* Patients with Rhabdomyolysis.\n* Patients who have had a contrast enhanced (with gadolinium) MRA (magnetic resonance angiography)\u002F or MRI within the last 3 months. (Contrast is a medication injected into a vein during a imaging examination that helps produce clearer images\u002Fpictures).",true,{"count":147,"type":22},113,"The purpose of this feasibility study is to determine if a new emerging technology called photoacoustic tomography (PAT) can be adapted for use in humans for the detection of chronic rheumatoid arthritis.",[28],[58],"2026-01-22",{"date":153,"type":34},"2026-01-23",{"date":155,"type":34},"2011-12-01",{"date":157,"type":22},"2027-01",{"name":159,"class":94},"University of Michigan",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":170,"conditions":171,"keywords":178,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":95},"100580823","effects-of-phytocannabinoids-on-immune-response-and-autophagy-during-chronic-immune-mediated-inflammatory-diseases-100580823","NCT06842316","Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases","In Vitro Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases","pCB-IMIDs","Inclusion Criteria:\n\n1. Male or female ≥ 18 years old\n2. Diagnosis confirmed by a rheumatologist of RA or spondyloarthropathy (with or without IBD) or psoriatic arthritis (with or without active psoriasis) or systemic lupus erythematosus or Sjögren's disease\n3. Patient who has expressed consent to participate in the study\n4. Patients affiliated to social security\n5. Treatments authorized as part of routine care: non-steroidal anti-inflammatory drugs (NSAIDs), level 1 to 3 analgesics, local corticosteroids, oral corticosteroid therapy (daily dose ≤15 mg\u002Fd), 5-aminosalicylic acid, salazopyrine, methotrexate, leflunomide, hydroxychloroquine, biotherapies and targeted therapies.\n\nExclusion Criteria:\n\n1. Patient who received intravenous corticosteroid therapy less than 4 weeks ago\n2. Patient receiving oral corticosteroid therapy with a daily dose \\>15 mg\u002Fday\n3. Consumption of CBD and\u002For recreational cannabis and\u002For positive saliva test for cannabis consumption and\u002For CBD\n4. Pregnant and lactating women\n5. Persons under guardianship or curatorship",{"count":169,"type":22},100,"Cannabis, in addition to its psychotropic properties, could have anti-inflammatory and immunomodulatory effects. Phytocannabinoids (pCBs) are a group of molecules naturally secreted by the cannabis plant. The major pCBs are cannabidiol (CBD) and Δ9-tetrahydrocannabinol Δ9 (THC). Only THC has psychotropic effects, which CBD does not have. Alongside these two main components, there is a wide variety of other molecules, such as other pCBs and terpenes which could increase the effects on immune system through synergistic interactions between these different compounds (\"entourage effect\").In vivo, pCBs essentially interfere with the endocannabinoid system, acting on many ubiquitous receptors, present on a significant number of different cell types. Numerous published studies show that pCBs have immunomodulatory and anti-inflammatory properties by acting on several of these receptors, whether through modulation of the immune response of different cell types, effects on cytokine networks, reduction of innate and adaptive responses and\u002For impact on cell survival or death (autophagy, proliferation\u002F apoptosis). The Immune-Mediated Inflammatory Diseases (IMIDs) affect 5 to 7% of the general population in Western countries, involve different organs (joints, skin, digestive tract) but share the same inflammatory mechanisms resulting from a dysregulation of the immune response. Our research focuses on the identification of the most effective phytochemical profile of pCBs, allowing an optimal effect on chronic inflammatory pathologies of interest among immune-mediated chronic inflammatory diseases (IMIDs). The pCB-IMIDs project is therefore part of an innovative translational project, around new therapeutic applications of medical cannabis (CannAppIMIDs). In our study, we will include 100 patients with one of IMIDs among Rheumatoid Arthritis, spondylarthritis, psoriatic arthritis, Sjogren disease and systemic lupus, at different stage and with different treatments. After patient's consent we will collect for research purposes an additional 40 ml of blood during a routine care blood test. Mononuclear and polynucleated blood cells will be exposed in vitro to different full-spectrum pCB extracts (full spectrum extract) including a CBD dominant and low THC extract (\\\u003C0.2%), 1 dominant THC extract, 1 balanced THC\u002FCBD extract and 1 dominant CBG extract. In this cross-sectional study, our objective will be to assess the biological effects of different pCB compositions on inflammatory profiles (concentrations of pro and anti-inflammatory cytokines and chemokines) and modulations of expression profiles (autophagy, apoptosis, and cannabinoid receptor expression profile).",[172,173,28,174,175,176,177],"Inflammatory Disorder of Immune System","Spondylitis, Ankylosing","Arthritis, Psoriatic","Inflammatory Bowel Diseases","Sjogren's Syndrome","Lupus Erythematosus, Systemic",[179,180,181,182],"IMIDs","phytocanabinoid","inflammatory effect","blood cells","2025-12-22",{"date":185,"type":34},"2025-12-30",{"date":187,"type":34},"2025-04-10",{"date":189,"type":22},"2027-04-09",{"name":191,"class":94},"Centre Hospitalier Régional d'Orléans",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":218},"100556694","phase-4-design-and-evaluation-of-an-individualized-biodrug-tapering-strategy-based-on-biodrug-dosage-the-monitora-study-100556694","NCT06528431","Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study","MONITORA","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Patients with a diagnosis of RA according to ACR\u002FEULAR 2010 criteria\n* Remission according to DAS28\\\u003C=2.6 for at least 6 months\n* Patient treated with ADA for at least 6 months. The patient is treated according to one of the following two strategies:\n* ADA 40 mg every two weeks (= every 14 days) according to the standard regimen\n* or ADA 40 mg every 3 weeks (= every 21 days)\n* A negative highly sensitive pregnancy test for women of Childbearing Potential\\*\n* Affiliated person or beneficiary of a social security scheme\n* Informed consent signed by the patient after information\n\nExclusion Criteria:\n\n* Incapacity or refusal to understand and \u002F or sign informed consent to participate in the study.\n* Existing pregnancy, lactation, or intended pregnancy within the next 15 months\n* Fibromyalgia associated to RA\n* Any dose of prednisone for RA treatment 6 months before inclusion\n* Patient deprived of liberty or patient under guardianship or curator ship.",{"count":200,"type":22},180,[202],"PHASE4","Rheumatoid arthritis (RA) is the most common inflammatory joint disorder. Since twenty year and the use of synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and biological (b)DMARD, remission can be reached. When remission is obtained, the physician has no recommendations for managing a step-down, and future guidelines will be useful to assist the clinician. Recent data suggest that tapering is feasible, but with high risk of flares. Flares are less frequent when bDMARD blood concentration is high. But, the optimal adalimumab concentration to keep before a step of tapering no targeting personal is unknown.",[28],[28,206,207,208],"Adalimumab","Remission management","step wedge trial","2025-12-19",{"date":211,"type":34},"2025-12-26",{"date":213,"type":34},"2024-12-19",{"date":215,"type":22},"2027-12-19",{"name":217,"class":94},"Centre Hospitalier Universitaire de Saint Etienne",8,{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":229,"briefSummary":230,"conditions":231,"keywords":232,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":244},"100594303","the-reboot-study-a-safety-study-of-abdominal-vagus-nerve-stimulation-for-moderate-to-severe-drug-refractory-rheumatoid-arthritis-100594303","NCT07017686","The Reboot Study: A Safety Study of Abdominal Vagus Nerve Stimulation for Moderate to Severe Drug Refractory Rheumatoid Arthritis","The Reboot Study: A Single Group, Open Label Safety Study of Abdominal Vagus Nerve Stimulation for Moderate to Severe Drug Refractory Rheumatoid Arthritis","Reboot","Inclusion Criteria:\n\n1. Male or female (18 - 75 years of age).\n2. Adult-onset rheumatoid arthritis (RA) (onset age 18 years or above) as defined by the 2010 ACR\u002FEULAR classification criteria, and Rheumatoid Factor (RF) or Cyclic Citrullinated Peptide (CCP) Antibody\u002FAnti-Citrullinated Peptide Antibody (ACPA) must be positive (above lab ranges).\n3. Moderate-severe active RA defined by at least 4\u002F28 tender and 4\u002F28 swollen joints.\n4. Have active disease that has not responded to a 3-month trial of, or has intolerance limiting a full 3 month trial of, at least 2 biologic and\u002For new targeted synthetic DMARDs (e.g. JAK inhibitors).\n5. Using a stable, continuous dose of at least 1 biological and\u002For synthetic DMARD for \\>8 weeks prior to study screening and for the duration of the trial.\n6. Women of childbearing age must not be pregnant or trying to become pregnant and must agree to use an effective method of contraception for the duration of their participation in the trial.\n7. Medicare eligibility.\n8. Provision of informed consent, in the form of a signed and dated informed consent form.\n\nExclusion Criteria:\n\n1. Unable or unwilling to provide written informed consent.\n2. Current diagnosis of major psychiatric disorder\u002Fs, or meets criteria as such on the Mini International Neuropsychiatric Interview (MINI), with the exception of stable, well controlled Major Depression or Anxiety Disorder.\n3. A medical condition that could interfere with study procedures, and\u002For confound evaluation of study endpoints, as determined by the Investigator.\n4. Medical conditions that have resulted in severe autonomic neuropathy e.g. poorly controlled type 2 diabetes or metabolic disease.\n5. History of previous surgical interventions including vagotomy, splenectomy, bariatric surgery.\n6. History of gastric hiatus hernia.\n7. Previously implanted active medical devices (e.g., dorsal root ganglion or spinal cord stimulators, cardiac pacemakers, automatic implantable cardioverter-defibrillators, drug pumps), or likely need for implantation of such devices within 6 months after start of this study.\n8. A condition that requires routine Magnetic Resonance Imaging (MRI) scans\n9. Is, in the opinion of the Principal Investigator\u002Fs not a suitable candidate for the trial.",{"count":228,"type":22},5,[82],"This open label clinical trial aims to assess the safety of abdominal vagus nerve stimulation (aVNS) for moderate to severe, adult-onset rheumatoid arthritis (RA) that has not responded to medication. The aVNS is an active medical device placed into the body to allow electrical stimulation of the abdominal vagus nerve. Participants will undergo stimulation treatment with the aVNS device from two to 24 weeks after the device is implanted by keyhole surgery. Safety, device performance and potential benefits will be assessed. Participants will be monitored for specific events for 5 years post surgery.",[28],[233,234],"Neuromodulation","Inflammatory disease","2025-09-18",{"date":237,"type":34},"2025-09-22",{"date":239,"type":22},"2025-09",{"date":241,"type":22},"2031-12",{"name":243,"class":94},"The Bionics Institute of Australia",3,{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":23,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":95},"100494361","ultrasound-to-guide-treatment-decisions-in-patients-with-rheumatoid-arthritis-according-to-a-t2t-approach-100494361","NCT05717179","Ultrasound to Guide Treatment Decisions in Patients With Rheumatoid Arthritis According to a T2T Approach","US-RA-T2T","Inclusion Criteria:\n\n1. Classification of RA according to the ACR-EULAR 2010 criteria\n2. Age of the patients: 18 to 84 years\n3. Patients with moderate or high disease activity according to CDAI (\\>10)\n4. Maximum of 2 clinically swollen joints out of a 44-joint count\n5. Current stable treatment with a single csDMARD or bDMARD or tsDMARD for at least 3 months\n6. No glucocorticoid therapy or stable glucocorticoid dose for at least 4 weeks and at a maximum dose of 5 mg\u002Fday prednisone equivalent.\n7. No corticosteroid intraarticular injection within 4 weeks\n8. Stable or absent dose of NSAIDs for at least 1 week\n9. Patients able and willing to give written informed consent and compliant with the requirements of the study protocol\n\nExclusion Criteria:\n\n1. Complete (clinically evident) destruction of any joint to be investigated by ultrasound as judged by the physician\n2. Current RA-related vasculitis or other active systemic (i.e. extraarticular) RA-manifestation except for rheumatoid nodules, which in the opinion of the investigator would expose the study subject to a high risk of morbidity or mortality\n3. Initial arthritis manifestations before the age of 18 years\n4. Planned surgery within the study period for any of the joints investigated either clinically or by sonography\n5. Current severe medical illness requiring hospitalization\n6. Active infection or active malignancy at screening \\\u003C5 years\n7. Any contraindication to b\u002Fts DMARDs according to the \"Summary of Product Characteristics\"\n8. Pregnancy or lactation","84 Years",{"count":254,"type":22},158,[82],"Population\n\nPatients with a diagnosis of Rheumatoid Arthritis (RA), moderate or high clinical disease activity (CDAI\\>10) despite conventional synthetic (cs)DMARD(s) or bs-ts-DMARDs therapy for ≥3 months, and a maximum of 2 swollen joints (out of 44 joints)\n\nStudy design\n\nRandomised multicentre, parallel-arm clinical study\n\nPrimary objective\n\nNon-inferiority of the experimental arm (i.e. clinical therapy together with ultrasound guided treatment decision) in comparison to the control arm (clinically guided decision) concerning the proportion of patients reaching low disease activity (CDAI ≤10) and a minimal clinical important improvement (MCII: improvement of ≥6 points if starting from moderate disease activity, any case starting from high disease activity and achieving low disease activity) or remission according to ACR\u002FEULAR index-based remission criteria (CDAI ≤2.8\u002FBoolean remission) at week 24.\n\nIntervention\n\nThis is a randomised multicentre, national, parallel-arm clinical study. Patients with a diagnosis of RA, moderate or high clinical disease activity (CDAI\\>10) despite conventional synthetic (cs)DMARD(s) or b-tsDMARDs therapy for ≥3 months, and a maximum of 2 swollen joints (out of 44 joints) will be included and randomized to one of the following two strategic arms:\n\n1. Clinical decision strategy: All patients receive a new course of b-ts-DMARDs, with or without concomitant cDMARD. If a CDAI ≤10 is not achieved after 12 weeks, patients are switched to a bDMARD or tsDMARD. The decision on which b\u002FtsDMARD to use at week 12 is at the discretion of the investigator.\n2. Clinical plus ultrasound-based decision strategy. All patients in this group will be evaluated by ultrasound at 44 joints. In case of clinically-verified plus ultrasound verified inflammation, patients will receive a new b-ts-DMARD while continuing or not background csDMARD(s) therapy. If a CDAI ≤10 is not achieved after 12 weeks, patients are again evaluated by ultrasound at 44 joints. In case clinically-verified plus ultrasound-verified inflammation is present, patients are switched to a bDMARD or tsDMARD. The decision on which b\u002FtsDMARD to use is at the discretion of the investigator. In case clinically-verified plus ultrasound-verified inflammation is absent, patients receive step-up pain therapy while background treatment will be continued.\n\nSample size\n\n158 patients\n\nTime plan\n\n* Total duration of the study: 72 months\n* Active phase for each patient: 48 weeks (24 weeks for the interventional treatment strategy and 24 weeks for follow-up visit)\n* Recruitment: 60 months",[28,258,259],"Ultrasound","Treat to Target","2025-05-09",{"date":262,"type":34},"2025-05-14",{"date":264,"type":34},"2023-02-22",{"date":266,"type":22},"2029-02",{"name":268,"class":94},"Italian Society for Rheumatology",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":277,"studyType":52,"phases":4,"briefSummary":278,"conditions":279,"keywords":284,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":4},"100572798","cellular-and-molecular-analysis-of-synovial-tissue-of-patients-with-arthritis-100572798","NCT06737952","Cellular and Molecular Analysis of Synovial Tissue of Patients With Arthritis","Inclusion Criteria:\n\n* Age \\>18 years\n* Clinically relevant arthritis in one or more joints as assessed by the treating rheumatologist, including RA, SpA, connective tissue disease and OA.\n\nExclusion Criteria:\n\n* Known allergies to local anesthetics\n* Family history of bleeding, history of increased bleeding tendency or prolonged bleeding, current treatment with oral anticoagulants or platelet aggregation inhibitors; Quick \\\u003C 65%, international normalised ratio (INR) ≥ 1.3, thrombocyte count \\\u003C 100'000\u002Fμl, activated partial thromboplastin time (aPTT) \\> 37 sec\n* Inability or insufficient knowledge of project language to understand the information given in the informed consent form",{"count":276,"type":22},90,"5 Days","This study aims to study the inflammatory response in various forms of arthritis.",[280,28,281,282,283],"Arthritis","Osteoarthritis","Spondyloarthritis","Synovitis",[285,286,287],"ultrasound-guided synovial biopsies (UGSB)","inflammatory response","synovial biopsy","2025-04-08",{"date":290,"type":34},"2025-04-11",{"date":292,"type":22},"2025-05",{"date":294,"type":22},"2029-12",{"name":296,"class":94},"University Hospital, Basel, Switzerland",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":308,"briefSummary":309,"conditions":310,"keywords":313,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":326,"locationsCount":4},"100580177","combining-virtual-reality-and-hypnosis-to-alleviate-chronic-pain-in-elderly-patients-with-hand-arthritis-100580177","NCT06833905","Combining Virtual Reality and Hypnosis to Alleviate Chronic Pain in Elderly Patients with Hand Arthritis","Combining Virtual Reality and Hypnosis to Alleviate Chronic Pain in Elderly Patients with Hand Arthritis: a Pilot Randomized Clinical Trial","VRHArthrisis","Inclusion Criteria:\n\n* Fluent in French\n* Being diagnosed with hand arthrisis\n* Reporting an invalidating chronic pain in hand related to the condition\n\nExclusion Criteria:\n\n* Experiencing a medical condition altering the ability to consent or participate in the study\n* Experiencing cognitive disorders; Experiencing sensory disorders (deafness, blindness)","100 Years",{"count":307,"type":22},80,[82],"The goal of this pilot randomized clinical trial is to test the efficacy of an intervention combining virtual reality and hypnosis on decreasing pain and improving quality of life in elderly patients with hand arthritis. The main questions it aims to answer are:\n\n* Does the intervention allow for an improvement of patient reported outcomes related to pain and quality of life?\n* Does the intervention allow for an improvement of physiological variables related to pain? Researchers will compare intervention group to a passive control group (i.e., waiting list with treatment as usual).\n\nParticipants in the intervention group will be provided a virtual reality headset allowing them to beneficiate from the virtual reality and hypnosis modules.",[280,311,28,312],"Arthritis\u002FArthrosis","Elderly",[314,315,316,317,318,319],"virtual reality","hypnosis","arthritis","pain","quality of life","elderly","2025-03-17",{"date":322,"type":34},"2025-03-19",{"date":324,"type":22},"2025-04",{"date":239,"type":22},{"name":327,"class":94},"Ciusss de L'Est de l'Île de Montréal",{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":351,"locationsCount":95},"100377197","evolution-and-treatments-of-chronic-inflammatory-systemic-diseases-100377197","NCT04191395","Evolution and Treatments of Chronic Inflammatory Systemic Diseases","Evolution and Treatments of Chronic Inflammatory Systemic Diseases: Implementation of a Hospital Cohort in the Gastroenterology, Dermatology and Rheumatology Departments of the University Hospital of Besançon","MISTIC","Inclusion Criteria:\n\n* Patients treated for IBD (MC, UC or indeterminate colitis) in the gastroenterology department of Besançon University Hospital\n* Subject meeting the clinical, morphological and histological diagnostic criteria for MC, UC or indeterminate colitis or\n* Patients treated for chronic inflammatory rheumatism (RA, SpA, PsA) in the rheumatology department of the University Hospital of Besançon Subject meeting the ACR 2010 classification criteria of RA or modified New York criteria of Ankylosing spondylitis or ASAS criteria of axial or peripheral SpA or CASPAR criteria of PsA or\n* Patients treated for chronic inflammatory skin disease (Psoriasis, Verneuil's disease) in the dermatology department of the University Hospital of Besançon\n\nExclusion Criteria:\n\n* Opposition of the patient\n* Patients in emergency situation, persons deprived of their liberty, protected minors or adults.",{"count":337,"type":22},3000,"Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points. The pathologies concerned are inflammatory bowel diseases (IBD - Crohn's disease \\[MC\\] and ulcerative colitis \\[RCH\\]), chronic inflammatory skin diseases (psoriasis or Verneuil's disease) and chronic inflammatory rheumatic diseases (rheumatoid arthritis \\[RA\\] and spondyloarthritis \\[SpA\\] including psoriatic arthritis \\[PsA\\]). Presenting one of these diseases is associated with a higher risk of having a second inflammatory pathology, whether the latter is ophthalmological, dermatological, rheumatological or gastroenterological. An association of extra-articular manifestations is observed in 10 to 30% of patients with SpA, and an association of extra-intestinal manifestations is observed in approximately 30% of patients with IBD. No common database for chronic systemic inflammatory diseases currently exists in France.",[175,340,341,28,282,342,343,344],"Ulcerative Colitis","Crohn Disease","Psoriatic Arthritis","Psoriasis","Verneuil's Disease","2024-11-25",{"date":347,"type":34},"2024-11-27",{"date":349,"type":34},"2019-12-11",{"date":294,"type":22},{"name":352,"class":94},"Centre Hospitalier Universitaire de Besancon",{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":23,"phases":362,"briefSummary":363,"conditions":364,"keywords":366,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":95},"100499984","fecal-microbial-transplantation-for-rheumatoid-arthritis-trial-100499984","NCT05790356","Fecal Microbial Transplantation for Rheumatoid Arthritis Trial","FeMiTRA","Inclusion Criteria:\n\n* 18-years old or older\n* RA diagnosis by ACR\u002FEULAR criteria \\[26\\]\n* Positive for the RA-associated antibodies, anti-citrullinated protein\u002Fpeptide antibodies (ACPA) and\u002For rheumatoid factor (RF)\n* Stable RA therapy \\> 6 months\n* Patient in remission or low disease activity by DAS28\n* Consents to study\n\nFecal Donor Inclusion Criteria:\n\n* A healthy donor who has a normal body mass index (BMI of 18.5-30) and who satisfies the following criteria will be selected from a pool of donors available in the Infectious Diseases clinic at St. Joseph's Hospital supervised by Dr. Silverman and screened for all transmissible agents. at the Microbiology and Immunology lab at St. Joseph's Hospital under Dr. Silverman for the study and screened for transmissible agents.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Current or recent \\[in the last 60 days\\] exposure to high dose oral (\\>30 mg of prednisone daily or equivalent), IV corticosteroids, biologic therapies or JAKi.\n* Patients who require inhaled steroids or local steroid injections are not excluded from the study\n* Has a diagnosis of immunodeficiency (HIV, transplantation, or autoimmune disease other than RA requiring immunosuppressive therapies), or currently receiving systemic steroid therapy (\\>10 mg prednisone daily or equivalent)\n* Received rituximab or other chemotherapeutic agent in the last 2 years.\n* Expected to require any other form of systemic or localized anti-neoplastic therapy while on study\n* Has a known history of a hematologic malignancy, primary brain tumor or sarcoma, or of another primary solid tumor, unless the patient has undergone potentially curative therapy with no evidence of that disease for five years. NOTE: This time requirement also does not apply to patients who underwent successful definitive resection of basal or squamous cell carcinoma of the skin, superficial bladder cancer, in situ cancers including cervical cancer, breast cancer, melanoma, or other in situ cancers.\n* Ongoing use of antibiotics\u002Fanti-virals or previous use of antibiotics\u002Fanti-virals in the last 3 months prior to the FMT procedure\n* Has an active infection requiring systemic therapy or requiring hospital admission in last 3 months.\n* Presence of a chronic intestinal disease (e.g. Celiac disease, malabsorption, colonic tumor, IBD)\n* Presence of absolute contra-indications to FMT administration\n* Toxic megacolon\n* Anaphylactic allergic reactions to food (e.g. shellfish, nuts, seafood, eggs)\n* Has serious uncontrolled concomitant illnesses, such as: cardiovascular disease (uncontrolled congestive heart failure, hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmia), severe obstructive or restrictive pulmonary diseases, cirrhosis or ALT\\>100, renal disease with GFR\\\u003C50 and uncontrolled psychiatric illness.\n* Patient has received a live vaccine within 4 weeks prior to the first dose of treatment\n* Insulin-dependent diabetes\n* Previous bariatric surgery\n* Chronic neutropenia (\\\u003C0.5) Currently participating in another clinical trial\n\nFecal Donor Exclusion Criteria:\n\n* Any underlying metabolic disease including; hypertension, hyperlipidemia, diabetes, insulin insensitivity, atherosclerosis\n* A history of any gastrointestinal or liver disorders or cancers. Including but not limited to; gastroesophageal reflux, peptic ulcer disease, celiac disease, inflammatory bowel disease (Crohn's disease or ulcerative colitis), microscopic colitis, motility disorders (including gastroparesis and irritable bowel syndrome) diverticular disease\n* Previous surgery to the intestine, liver or gallbladder (except remote appendectomy)\n* History of any malignancy\n* Use within 3 months of any antibiotics\n* Hospitalization within 3 months\n* Recent travel to a developing country (within 3 months).\n* New Sexual Partner (within 3 months)\n* Street drug use, family history of diabetes, early onset coronary disease or gastrointestinal or liver disease, colon cancer, familial malignancy\n* Psychiatric history (major affective disorder, psychotic illness, ongoing use of any psychiatric medications)\n* Any positive laboratory results for a transmissible pathogen\n* Alcohol intake with a cut off value of \\\u003C10g\u002Fd in women and \\\u003C20g\u002Fd in men\n* Currently participating in another clinical trial that may alter fecal composition.",{"count":361,"type":22},30,[82],"This clinical trial will investigate the effects of capsules containing stool from healthy donors, called fecal microbial transplant (FMT), in rheumatoid arthritis patients.",[280,28,365],"Fecal Microbiota Transplantation",[280,367,368,369,370,371,372,373,374],"Rheumatoid","Rheumatoid Arthritis","clinical trial","fecal matter transplantation","fecal matter transplant","faecal","autoimmune","proof of concept","2024-08-19",{"date":377,"type":34},"2024-08-21",{"date":379,"type":34},"2023-08-01",{"date":381,"type":22},"2026-04-01",{"name":383,"class":94},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":95},"100553908","impact-of-a-high-fiber-diet-on-the-microbiome-and-disease-activity-in-patients-with-rheumatoid-arthritis-100553908","NCT06492200","Impact of a High-fiber Diet on the Microbiome and Disease Activity in Patients With Rheumatoid Arthritis","Einfluss Ballaststoffreicher Ernährung Auf Das Mikrobiom Und Die Krankheitsaktivität Von Patientinnen Und Patienten Mit Rheumatoider Arthritis","Inclusion Criteria:\n\n* Patients over 18 years old\n* Diagnosis of Rheumatoid Arthritis according to the ACR criteria of 2010\n* The patient can understand the scope of the study and consents in writing to participate.\n\nExclusion Criteria:\n\n* Age under 18\n* Lack of consent capability\n* Insufficient knowledge of the German language\n* Chronic inflammatory bowel disease\n* Liver cirrhosis\n* History of mechanical ileus\n* Patients with altered gastrointestinal passage (e.g., stoma patients)\n* Use of antibiotics within the past three months\n* Use of ground psyllium husks four weeks prior to study inclusion","99 Years",{"count":393,"type":22},52,[82],"The goal of this clinical trial is to learn if increasing dietary fiber can improve the gut microbiome and reduce disease activity in adults with rheumatoid arthritis (RA). The main questions it aims to answer are:\n\n* Can a higher fiber diet improve gut bacteria and produce beneficial short-chain fatty acids (SCFAs)?\n* Does a higher fiber diet reduce RA symptoms and help with weight loss?\n\nResearchers will compare two groups: one group will receive dietary counseling and take 10 grams of psyllium husk daily, while the other group will continue their usual diet.\n\nParticipants will:\n\n* Complete dietary questionnaires at the start, 6 months, and 12 months.\n* Provide stool samples for gut bacteria and SCFA analysis.\n* Have their RA activity and body weight monitored regularly.\n* Receive regular phone calls to support the dietary changes.\n\nThe study will involve adults with diagnosed RA who can provide informed consent and meet other inclusion criteria.",[28],"2024-07-01",{"date":399,"type":34},"2024-07-09",{"date":401,"type":34},"2024-06-01",{"date":403,"type":22},"2026-12-30",{"name":405,"class":94},"Wuerzburg University Hospital",{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":423,"locationsCount":95},"100418678","characterization-of-immunogenicity-of-tnf-inhibitors-in-arthritis-patients-with-poorer-treatment-response-100418678","NCT04731831","Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.","Characterization of Immunogenicity of Tumor Necrosis Factor Inhibitors in Arthritis Patients With Poorer Treatment Response Due to Gender, Obesity and Smoking Status.","Inclusion Criteria:\n\n* Patients \\> 18 years\n* Diagnosed with RA, PsA or AS.\n* Starting treatment with infliximab or adalimumab.\n* Co- treatment with csDMARD or glucocorticoid is acceptable.\n* No new bDMARD is initiated at the time of sampling.\n\nExclusion Criteria:\n\n\\-",{"count":414,"type":22},120,"The aim of the study is to explore whether the influence of gender, tobacco smoking and obesity on treatment response in tumor necrosis factor inhibitors (TNFIs) can be explained by high degree of inflammation, human leucocyte antigen (HLA) type, autoantibodies, TNF and TNFI concentration and presence of ADA.",[28,174,173],"2024-06-27",{"date":419,"type":34},"2024-06-28",{"date":421,"type":34},"2020-08-01",{"date":185,"type":22},{"name":424,"class":94},"Aalborg University Hospital",{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":433,"enrollmentInfo":434,"targetDuration":4,"studyType":23,"phases":436,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":450,"locationsCount":4},"100537090","towards-telemonitoring-in-immune-mediated-inflammatory-diseases-implementation-of-a-mixed-attention-model-imidoc-100537090","NCT06273306","Towards Telemonitoring in Immune-Mediated Inflammatory Diseases: Implementation of a Mixed Attention Model (IMIDOC)","Towards Telemonitoring in Immune-Mediated Inflammatory Diseases: Implementation of a Mixed Attention Model","IMIDOC","Inclusion Criteria:\n\n* Clinical diagnosis with Rheumatoid Arthritis or Spondylarthritis\n* Treatment with biologic or targeted disease modifying antirheumatic drugs.\n* Ability to use smartphone.\n\nExclusion Criteria:\n\n* only patients with conditions that hinder or prevent the use of a mobile application (blindness, mental retardation, dementia, digitalfilliteracy).","80 Years",{"count":435,"type":22},360,[82],"The main objective is to evaluate the implementation of a hybrid care model called the mixed attention model (MAM) in clinical practice and to evaluate whether its implementation improves clinical outcomes compared to conventional follow-up.\n\nThis is a multicenter prospective observational study involving 360 patients with rheumatoid arthritis (RA) and Spondylarthritis (SpA) from five Spanish Hospitals. Patients will be followed-up by the MAM protocol, which is a care model that incorporates the use of digital tool consisting of a mobile application (App) that patients can use at home and that professionals can review asynchronously to detect incidents and to follow their patients; clinical evolution between face-to-face visits. Another group of patients, whose follow-up will be conducted in accordance with a traditional face-to-face care model, will be assessed as the control group. Sociodemographic characteristics, treatments, laboratory parameters, assessment of tender and swollen joints, visual analogue scale for pain and electronic patient reported outcome reports (ePROs) will be collected for all subjects. In the MAM group, these items will be self-assessed both by the mobile App and during face-to-face visits with rheumatologist, who will do the same for patients included in the traditional care model. Patients will be able to report any incidence related to their disease or treatment through the mobile App.",[439,440,441,442,28,443],"Telemedicine","Telehealth","eHealth","Rheumatic Diseases","Spondylarthritis","2024-02-15",{"date":446,"type":34},"2024-02-22",{"date":448,"type":22},"2024-03-15",{"date":38,"type":22},{"name":451,"class":94},"Instituto de Investigación Hospital Universitario La Paz",{"id":453,"slug":454,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":459,"enrollmentInfo":460,"targetDuration":462,"studyType":52,"phases":4,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":95},"100507129","impact---andhealth-autoimmune-research-registry-100507129","NCT05883371","IMPACT - AndHealth Autoimmune Research Registry","Investigating Mechanisms of Participatory Autoimmune Condition Treatment (IMPACT): An Outcomes Research Registry of a Comprehensive Approach to Autoimmune Disorders","Inclusion Criteria:\n\n1. Adults 18 to 70 years of age\n2. Able to understand and write English\n3. Voluntarily consent to the study and understand its nature and purpose including potential risks and side effects\n4. Documented diagnosis and current use\u002Frecommendation for biologic or DMARD medications to treat rheumatoid arthritis, psoriatic arthritis, psoriasis, or ankylosing spondylitis.\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding, or planning to become pregnant in the next 12 months\n2. Advanced liver or kidney disease\n3. Previous organ transplant or awaiting organ transplant\n4. Actively being treated for cancer\n5. Poorly-controlled mental illness (i.e., schizophrenia, bipolar, current eating disorder)\n6. Has a terminal illness\n7. Current opioid use","70 Years",{"count":461,"type":22},2500,"5 Years","This is a patient research registry aimed at evaluating the effectiveness of a comprehensive, root-cause medical approach (\"AndHealth program\") for autoimmune disorders. This approach involves a combination of pharmacological and non-pharmacological therapies offered under the care of a licensed physician with the support of health coaches. While protocol guidance is provided, the therapeutic approach is personalized to the individual needs of patients. The autoimmune disorders of focus in this registry include rheumatoid arthritis, psoriatic arthritis, psoriasis and ankylosing spondylitis. A variety of validated labs, patient-reported outcomes, and medication usage will be assessed among participating patients over a period of up to five years to evaluate the long-term effectiveness of this approach.",[28,174,343,465,466],"Ankylosing Spondylitis","Autoimmune Diseases","2023-06-28",{"date":469,"type":34},"2023-06-29",{"date":471,"type":34},"2023-06-08",{"date":473,"type":22},"2028-05-22",{"name":475,"class":41},"AndHealth",{"id":477,"slug":478,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":482,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":484,"conditions":485,"keywords":487,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":244},"100489801","novel-complex-radiodiagnostics-of-peripherial-arthropathies-100489801","NCT05657847","Novel Complex Radiodiagnostics of Peripherial Arthropathies","Inclusion Criteria:\n\n* Rheumatoid arthritis (EULAR\u002FACR Criteria) \u002F Psoriatic arthritis (CASPAR Criteria)\u002F Crystal arthropathies\n* signed informed consent\n\nExclusion Criteria:\n\n* age: \\\u003C18 years, \\> 100 years\n* pregnant\n* breastfeeding",{"count":483,"type":22},500,"Chronic peripherial arthritides are common diseases with soaring public health consequences. Our goal is to assess the role of photon-counting detector computed tomography in the diagnostics of peripherial arthropathies.",[28,174,486],"Crystal Arthropathies",[488],"photon-counting detector computer tomography, magnetic resonance imaging, radiography, rheumatoid arthritis, psoriatic arthritis, crystal arthropathies","2022-12-12",{"date":491,"type":34},"2022-12-20",{"date":493,"type":34},"2022-03-07",{"date":495,"type":22},"2027-02-01",{"name":497,"class":94},"Semmelweis University",{"id":499,"slug":500,"hasResults":11,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":433,"enrollmentInfo":505,"targetDuration":4,"studyType":23,"phases":507,"briefSummary":508,"conditions":509,"keywords":510,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":519,"locationsCount":95},"100487381","phase-4-the-clinical-efficacy-of-immunomodulators-in-ra-patients-100487381","NCT05626348","The Clinical Efficacy of Immunomodulators in RA Patients","The Clinical Study to Observe the Efficacy and Safety of Immunomodulators in Rheumatoid Arthritis Patients for 6 Months Treatment in China","Inclusion Criteria:\n\n\\-\n\n1.Patients with RA who meet ACR 1987 rheumatoid arthritis classification criteria or ACR\u002FEULAR 2010 rheumatoid arthritis Classification Criteria and have knee dysfunction.\n\n1. ACR 1987 rheumatoid arthritis classification criteria\n\n   1. morning stiffness lasting at least 1 hour (≥6w)\n   2. there are 3 or more joint areas swollen (≥6w)\n   3. swelling of the wrist, metacarpophalangeal, and proximal phalangeal joint areas (≥6w)\n   4. symmetrical arthrogryposis (≥6w)\n   5. hand x-ray changes (at least osteoporosis and joint space narrowing)\n   6. positive rheumatoid factor (titer \\> 1:32) RA can be diagnosed by meeting 4 of the above 7 items\n2. ACR\u002FEULAR 2010 rheumatoid arthritis Classification Criteria\n\n   1. Involved joints\n\n      \\- 1 large joint (0 points)\n      * 2-10 large joints (1 point)\n      * 1-3 small joints (with or without large joints) (2 points)\n      * 4-10 small joints (with or without large joints) (3 points)\n      * more than 10 small joints (at least one small joint) (5 points)\n   2. Serological indicators\n\n      * RF and ACPA negative (0 points)\n      * RF and ACPA, at least one of which is low titer positive. (2 points)\n      * RF and ACPA with at least one high titer positive (3 points)\n   3. Acute chronotropic reactants\n\n      * Both CRP and ESR normal (0 points)\n      * Abnormal CRP or ESR (1 point)\n   4. Duration of synovitis\n\n      * \\\u003C6 weeks (0 points)\n      * ≥6 weeks (1 point)\n\n        2.Patients with OA who meet the 1995 Classification Criteria for OA and have knee dysfunction 1995 Classification Criteria for Osteoarthritis of the Knee Clinical criteria\n\n        a. Knee pain most of the time in the last 1 month b. Bone rubbing sound c, morning stiffness ≤ 30 minutes d, age ≥ 38 years e, with bony enlargement Knee OA can be diagnosed if a+b+c+d or a+b+e is met\n\n        3.Age-sex matched healthy volunteers who checked in our hospital.\n\n        4.Age \\> 18 years old;\n\n        5.Voluntarily participate in this study and sign an informed consent form\n\nExclusion Criteria:\n\n1. Patients with combined active hepatitis\n2. Patients with active tuberculosis\n3. Patients withinfection and malignancy",{"count":506,"type":22},400,[202],"This study includes naive patients and csDMARDs-IR RA patients, treated with different regimens such as Iguratimod combination of different csDMARDs, or csDMARD with TNF inhibitors for 24 weeks. The disease activity and drug response will be observed. The immune disorder and synovial function will be evaluated at the same time.",[28],[511,512],"csDMARDs","TNFi","2022-11-28",{"date":515,"type":34},"2022-11-29",{"date":517,"type":34},"2021-12-22",{"date":38,"type":22},{"name":520,"class":94},"Qilu Hospital of Shandong University",{"id":522,"slug":523,"hasResults":11,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":280,"eligibilityCriteria":527,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":530,"conditions":531,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":538,"locationsCount":95},"100444053","persistence-of-biological-treatment-and-inhibitors-of-jak-kinases-in-patients-with-rheumatoid-arthritis-100444053","NCT05062421","Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.","Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities.","Inclusion Criteria:\n\n* Patients aged ≥18 years.\n* With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR \u002F EULAR criteria.\n* Who have received at least one of the doses of the study drugs.\n* In follow-up in the consultations of the UGC of Rheumatology of the HUVM.\n* With at least two complete evaluations (baseline and final) of clinical variables.\n\nExclusion Criteria:\n\n* Patients where the medical records lack sufficient baseline and final variables to perform the analysis.\n* Patients in whom more than 50% of the variables to be collected are missing in the data collection.",{"count":529,"type":22},540,"One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).\n\nThese patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.",[28],"2021-11-15",{"date":534,"type":34},"2021-11-17",{"date":536,"type":34},"2021-04-01",{"date":38,"type":22},{"name":539,"class":94},"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla"]